

25 August 2025

## Botanix appoints Dr Patricia Walker to the Board

### Key highlights

- Botanix proudly welcomes Dr Patricia Walker, MD, PhD, to their Board of Directors, effective 25 August 2025
- Dr Walker has extensive experience on the boards of leading pharmaceutical companies
- With over 60 publications in medical and scientific journals to her credit, Dr Walker's thought leadership in dermatology is evident
- As a practising dermatologist, she has an in-depth understanding of the marketplace and patient needs

**Philadelphia and Phoenix US, 25 August 2025:** Clinical dermatology company, Botanix Pharmaceuticals Limited (ABN 70 009 109 755) (ASX:BOT, "Botanix" or "the Company"), is proud to welcome Dr Patricia Walker, MD, PhD, to their Board of Directors, effective 25 August 2025. She brings extensive experience and learnings from previous board affiliations with leading dermatology companies. Her impactful thought leadership in dermatology is readily apparent with over 60 publications in medical and scientific journals and an outstanding number of learned lectures to her credit. Dr Walker is the recipient of over two dozen academic and professional honours.

She brings a wealth of knowledge in drug development for key dermatology products, including Tazorac®, Botox Cosmetic, Juvéderm®, Hylaform®, Captique®, Lap-Band®, Inamed Silicone gel-filled breast implants, and Kybella from her engagements with Allergan, Allergan Medical Aesthetics, Inamed, and Kythera Biopharmaceuticals. Dr Walker also led the development of Botanix's lead product, Sofdra™ (sofpironium) topical gel, 12.45% from a preclinical asset to Phase 3 prior to its acquisition by Botanix.

Dr Walker previously served as Chief Medical Advisor for Botanix Pharmaceuticals through her consulting company, Walker Consulting, which continues to work with prominent dermatology pharmaceutical companies.

**Botanix Executive Chairman Vince Ippolito, commented:** *"Dr Walker has a rare and unique skill set including both product development and business acumen that makes her an outstanding addition to the Company's Board."*

*"In addition to Dr Walker's prowess at identifying and developing drug products, she contributes the insights of a working dermatologist."*

Dr Walker completed her medical degree and dermatology residency training at the University of Iowa College of Medicine. She also completed a prestigious research fellowship at the National Institute of Health's Dermatology Branch. Dr Walker put her experience to work teaching the next generation of dermatologists as a member of the Clinical Faculty, Department of Dermatology, University of California, Irvine.

Dr Walker has shown a great passion for the oversight of research and new product development – all stages from discovery to global market approvals. She is also experienced in securing corporate financing, product licenses, joint development efforts and initial public offerings.

**Botanix Chief Executive Officer, Dr Howie McKibbon, commented:** *“Dr Patricia Walker’s knowledge and experience have been of great value to Botanix, and I expect even greater contributions from her as a Board member.”*

*“With Dr Walker’s experience, from product discovery to global market approvals, she will continue to be instrumental in evaluating potential product acquisitions for Botanix.”*

This ASX announcement is authorised for release by the Board.

#### About Botanix Pharmaceuticals

Botanix Pharmaceuticals Limited (ASX: BOT) is a dermatology company based in Philadelphia and Phoenix (US), which has received FDA approval for its lead product *Sofdra*<sup>™</sup> for the treatment of primary axillary hyperhidrosis. *Sofdra* is the first and only new chemical entity approved by FDA to treat primary axillary hyperhidrosis and presents a novel safe and effective solution for patients who have lacked treatment options for this socially challenging medical condition.

To learn more, please visit: <http://www.botanixpharma.com/>

#### For more information, please contact:

##### General enquiries

Corporate Communications  
Botanix Pharmaceuticals  
P: +61 8 6555 2945  
[investors@botanixpharma.com](mailto:investors@botanixpharma.com)

##### Investor enquiries

Hannah Howlett  
WE Communications  
P: +61 450 648 064  
[hhowlett@we-worldwide.com](mailto:hhowlett@we-worldwide.com)

##### Media enquiries

Haley Chartres  
H^CK  
P: +61 423 139 163  
[haley@hck.digital](mailto:haley@hck.digital)

For personal use only

### Cautionary Note on Forward-Looking Statements

Forward-looking statements can generally be identified by the use of forward-looking words such as, “expect”, “anticipate”, “likely”, “intend”, “should”, “could”, “may”, “predict”, “plan”, “propose”, “will”, “believe”, “forecast”, “estimate”, “target”, “outlook”, “guidance” and other similar expressions and include, but are not limited to, plans and prospects for the Company, the Company’s strategy, future operations, the expected timing and/or results of regulatory approvals and prospects of commercialising product candidates or research collaborations with its partners, including in Japan, the outcome and effects of *Sofdra*<sup>™</sup> and the market for *Sofdra*. Indications of, and guidance or outlook on, future earnings or financial position or performance are also forward-looking statements. The forward-looking statements contained in this Presentation are not indications, guarantees or predictions of future performance and involve known and unknown risks and uncertainties and other factors, many of which are beyond the control of Botanix, and may involve significant elements of subjective judgement and assumptions as to future events which may or may not be correct. Investors should consider the forward-looking statements contained in this Presentation in light of those disclosures and not place undue reliance on such statements. Except as required by law or regulation, Botanix undertakes no obligation to update forward-looking statements.

For personal use only

## **Sofdra™ Important Safety Information & Indication**

### **Indication**

*Sofdra* (sofipironium) topical gel, 12.45% is a prescription anticholinergic medicine used on the skin (topical) to treat excessive underarm sweating (primary axillary hyperhidrosis) in adults and children 9 years of age and older.

### **IMPORTANT SAFETY INFORMATION**

***Sofdra* is for use on the skin in the underarm area only. Wash your hands right away after you apply *Sofdra*. Do not touch your underarms after applying *Sofdra*. *Sofdra* is flammable. Avoid heat and flame while applying *Sofdra*.**

### **Who should not use *Sofdra*?**

Do not use *Sofdra* if you have certain medical conditions that can be made worse by taking an anticholinergic medicine such as glaucoma, severe ulcerative colitis (UC) or certain other serious bowel problems associated with severe UC, myasthenia gravis, and Sjogren's syndrome.

### **What should I tell my healthcare provider before using *Sofdra*?**

- **Tell your healthcare provider about all of your medical conditions**, including bladder or kidney problems, problems passing urine, if you are pregnant or breastfeeding, or plan to become pregnant or breastfeed. It is not known if *Sofdra* will harm your unborn baby or pass into your breast milk.
- **Tell your healthcare provider about all the medicines you take**, including prescription and over-the-counter medicines, especially any anticholinergic medicines.

### **What are possible side effects of *Sofdra*?**

#### **Serious side effects may include:**

- **Blurred vision.** Stop using *Sofdra*, call your healthcare provider right away, and do not drive or operate machinery or do hazardous work until your vision is clear.
- **New or worsened urinary retention.** Stop using *Sofdra* and call your healthcare provider right away if you experience difficulty urinating, urinating frequently, urination in a weak stream or drips, full bladder or difficulty emptying your bladder.

**The most common side effects of *Sofdra* include** dry mouth; blurred vision; pain, redness, swelling, itching, and irritation in the underarm area; dilation of the pupils of your eyes (mydriasis); and problems with urination. These are not all of the possible side effects of *Sofdra*. Call your doctor for medical advice about side effects.

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit [www.fda.gov/medwatch](http://www.fda.gov/medwatch) or call 1-800-FDA-1088. You may also report side effects to Botanix at 1-866-763-6337.

**Keep *Sofdra* and all medicines out of the reach of children.**